While all tested cell lines exhibited robust LAMP1 expression by flow cytometry, we selected MDA-MB-231 (breast adenocarcinoma) and Caco-2 (colon adenocarcinoma) as our primary models for subsequent experiments based on their superior expression profiles and experimental tractability. Here, LAMP1 is linked to colon adenocarcinoma.